<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

LONG-TERM MEDICATION USE AND POLYPHARMACY IN OLDER ADULTS

dc.contributor.authorEgici, Memet Taskin
dc.contributor.authorBagci, Hasan
dc.contributor.authorGurel, Nermin
dc.date.accessioned2026-10-09T21:52:18Z
dc.date.issued2021
dc.departmentYüksek İhtisas Üniversitesi
dc.description.abstractIntroduction: In Turkey, long-term medication use reports help patients covered by universal health insurance to access drugs without having to make co-payments. Using these reports, the present study investigates the prevalence of polypharmacy and specifically, its relationship with age, gender, diagnosis, number of diseases, and various clinical branches. Materials and Methods: In this descriptive retrospective study, anonymous data obtained from long-term medication use reports were analyzed using SPSS and Microsoft Excel. Results: A total of 66,995 samples were examined, 60.7% of which were female patients. The average number of active substances was 2.78 +/- 2.11, the rate of reports containing five or more active substances (polypharmacy) was 16.1% (10.757 samples), the distribution by gender was 62.7% female and 37.3% male. The distribution of polypharmacy by age groups was 60.1% in the 65-74 age group, 32.5% in the 74-85 age group, and 7.4% in the >= 85 age group. The most common diagnoses were diabetes mellitus (37.8%), hypertension (12.9%), and hyperlipidemia (8.2%). The clinical branches accounting for the highest rate of polypharmacy were internal medicine (65.1%), cardiology (10%), and chest diseases (6.1%). Acetylsalicylic acid was the most prescribed substance (12.3%) among 657 active substances. Conclusion: The results of this study can be used by regulatory authorities and in clinical practice by physicians. Using a clinical decision system supported by guidelines can help clinicians to optimize drug therapy and reduce polypharmacy in older adults. To reduce inappropriate drug use, such as the Beers, STOPP-START, and TIME criteria were recommended to be used in decision support systems.
dc.identifier.doi10.31086/tjgeri.2021.207
dc.identifier.endpage133
dc.identifier.issn1304-2947
dc.identifier.issn1307-9948
dc.identifier.issue2
dc.identifier.orcid0000-0003-2319-5739
dc.identifier.startpage122
dc.identifier.trdizinid509669
dc.identifier.urihttps://doi.org/10.31086/tjgeri.2021.207
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/509669
dc.identifier.urihttps://hdl.handle.net/20.500.12794/3893
dc.identifier.volume24
dc.identifier.wosWOS:000664872200003
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynak.digerScience Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
dc.language.isoen
dc.publisherGunes Kitabevi Ltd Sti
dc.relation.ispartofTurkish Journal of Geriatrics-Turk Geriatri Dergisi
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.relation.sdgGoal-03: Good Health and Well-Being
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260922
dc.subjectAged
dc.subjectChronic Diseases
dc.subjectMultimorbidity
dc.subjectPolypharmacy
dc.subjectPrescriptions
dc.titleLONG-TERM MEDICATION USE AND POLYPHARMACY IN OLDER ADULTS
dc.typeArticle

Files